Abstract: Provided are compositions and methods for treating or ameliorating a cancer by targeting cell surface-expressed ?v?3 (avb3) polypeptides in Cancer Stem Cells (CSCs) to kill the CSCs, thus treating ameliorating or slowing the development of cancers caused or initiated by or sustained by cancer or tumor cells, or Cancer Stem Cells (CSCs), expressing ?v?3 polypeptides on their cell surfaces. Provided are compositions and methods for targeting and killing ?v?3-positive Cancer Stem Cells (CSCs) and treating drug resistant cancers. In alternative embodiments, compositions and methods as provided herein use an antibody that can specifically bind to human ?v?3 that also comprises an Fc portion that can mediate antibody-dependent un-mediated cytotoxicity (ADCC) killing of cancer or tumor cells by macrophages; for example, use a humanized antibody to ?v?3 that has been modified to include an engineered Fc portion that specifically binds to human macrophages.

Abstract: The present invention relates to chimeric binding agents and compositions comprising the same. The invention further relates to polynucleotides encoding the chimeric binding agent and vectors and host cells comprising the same. The invention further relates to methods of using the chimeric binding agents to mediate antibody-dependent cellular cytotoxicity of epithelial cancer cells and methods of treating epithelial cell cancers.

Abstract: In alternative embodiments, provided are compositions and methods for treating or ameliorating an advanced cancer such as a drug resistant or metastatic cancer which express ?v?3 polypeptides on their cell surfaces, or for killing Cancer Stem Cells (CSCs) which express ?v?3 polypeptides on their cell surfaces, by using human or humanized antibodies capable of specifically binding cell surface-expressed ?v?3 (avb3) polypeptides whose Fc region has a selective affinity to human Fc?R1 (CD64), but not to other Fc?Rs, on effector cells such as macrophages, neutrophils, and dendritic cells. By administering these antibodies to an individual in need thereof, these human or humanized antibodies are capable of treating, ameliorating or slowing the development of the advanced cancer or drug resistant cancer, or a cancer caused or initiated by or sustained by an advanced cancer or drug resistant cancer cell, or a Cancer Stem Cell (CSC).

Abstract: Provided are compositions and methods for treating or ameliorating a cancer by targeting cell surface-expressed ALPHA-V BETA-3 polypeptides in Cancer Stem Cells (CSCs) to kill the CSCs, to treat cancers caused or initiated by cancer or tumor 10 cells, or Cancer Stem Cells (CSCs), expressing ALPHA-V BETA-3 polypeptides on their cell surfaces. Provided are compositions and methods for targeting and killing ALPHA-V BETA-3-positive Cancer Stem Cells (CSCs) and treating drug resistant cancers. In alternative embodiments, compositions and methods as provided herein use an antibody that can specifically bind to human ALPHA-V BETA-3 that also comprises an Fc portion that can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) killing of cancer cells by macrophages; for example, use a humanized antibody to ALPHA-V BETA-3 that has been modified to include an engineered Fc portion that specifically binds to human macrophages.